Exelixis Inc (EXEL)

11.04
0.17 1.60
NASDAQ : Health Care
Prev Close 10.87
Open 10.91
Day Low/High 10.88 / 11.07
52 Wk Low/High 3.55 / 11.74
Volume 961.93K
Avg Volume 6.29M
Exchange NASDAQ
Shares Outstanding 230.33M
Market Cap 2.67B
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

3 Biotech-Investing Mistakes to Avoid

3 Biotech-Investing Mistakes to Avoid

These are the biggest errors that I've made over the years.

Trade-Ideas: Exelixis (EXEL) Is Today's

Trade-Ideas: Exelixis (EXEL) Is Today's "Perilous Reversal" Stock

Trade-Ideas LLC identified Exelixis (EXEL) as a "perilous reversal" (up big yesterday but down big today) candidate

Why Exelixis (EXEL) Stock Is Soaring Today

Why Exelixis (EXEL) Stock Is Soaring Today

Exelixis (EXEL) stock was trading sharply higher this afternoon after reporting second-quarter financial results.

Don't Roll the Dice on Central Bank News

Don't Roll the Dice on Central Bank News

The bears are trying it out on the Bank of England news today, but they may get squeezed.

Exelixis Announces Second Quarter And Year To Date 2016 Financial Results And Provides Corporate Update

Exelixis Announces Second Quarter And Year To Date 2016 Financial Results And Provides Corporate Update

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the second quarter of 2016 and provided an update on progress toward delivering upon its key 2016 corporate objectives, as well as commercial and clinical...

4 Tech and Biotech Stocks With Momentum to Watch

4 Tech and Biotech Stocks With Momentum to Watch

Here are four biotech and technology stocks showing strong technical momentum.

Exelixis To Release Second Quarter 2016 Financial Results On Wednesday, August 3, 2016

Exelixis To Release Second Quarter 2016 Financial Results On Wednesday, August 3, 2016

Exelixis, Inc. (NASDAQ: EXEL) announced today that its second quarter 2016 financial results will be released on Wednesday, August 3, 2016 after the markets close.

Biotech Stock Mailbag: Heron, Exelixis

Biotech Stock Mailbag: Heron, Exelixis

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

'Mad Money' Lightning Round: I'm Sticking With Wells Fargo

'Mad Money' Lightning Round: I'm Sticking With Wells Fargo

Cramer is taking Honeywell over Boeing and is nervous about AIG.

Jim Cramer's 'Mad Money' Recap: We've Seen This 'Brexit' Movie Before

Jim Cramer's 'Mad Money' Recap: We've Seen This 'Brexit' Movie Before

Sure, we're in a bad moment but is it really worth ditching high-quality stocks to run for the hills? Cramer asks.

Trade-Ideas: Exelixis (EXEL) Is Today's Strong On High Relative Volume Stock

Trade-Ideas: Exelixis (EXEL) Is Today's Strong On High Relative Volume Stock

Trade-Ideas LLC identified Exelixis (EXEL) as a strong on high relative volume candidate

Today's Perilous Reversal Stock: Exelixis (EXEL)

Today's Perilous Reversal Stock: Exelixis (EXEL)

Trade-Ideas LLC identified Exelixis (EXEL) as a "perilous reversal" (up big yesterday but down big today) candidate

Exelixis (EXEL) Stock Gains on Positive Trial Results for Kidney Cancer Treatment

Exelixis (EXEL) Stock Gains on Positive Trial Results for Kidney Cancer Treatment

Exelixis (EXEL) stock is higher in pre-market trading on Monday after the company announced positive trial data for its treatment for advanced kidney cancer.

Exelixis And Its Partner Ipsen Announce Positive Overall Survival Results From Subgroup Analyses Of Phase 3 Trial Of CABOMETYX™ (cabozantinib) Tablets In Advanced Renal Cell Carcinoma At 2016 ASCO Annual Meeting

Exelixis And Its Partner Ipsen Announce Positive Overall Survival Results From Subgroup Analyses Of Phase 3 Trial Of CABOMETYX™ (cabozantinib) Tablets In Advanced Renal Cell Carcinoma At 2016 ASCO Annual Meeting

Regulatory News: Exelixis, Inc. (NASDAQ:EXEL) and Ipsen (Euronext: IPN; ADR: IPSEY) today announced the presentation of positive data from subgroup analyses of the pivotal METEOR trial comparing CABOMETYX™...

Exelixis And Its Partner Ipsen Announce Positive Overall Survival Results From Subgroup Analyses Of Phase 3 Trial Of CABOMETYX™ (cabozantinib) Tablets In Advanced Renal Cell Carcinoma At 2016 ASCO Annual Meeting

Exelixis And Its Partner Ipsen Announce Positive Overall Survival Results From Subgroup Analyses Of Phase 3 Trial Of CABOMETYX™ (cabozantinib) Tablets In Advanced Renal Cell Carcinoma At 2016 ASCO Annual Meeting

Exelixis, Inc. (NASDAQ:EXEL) and Ipsen (Euronext: IPN; ADR: IPSEY) today announced the presentation of positive data from subgroup analyses of the pivotal METEOR trial comparing CABOMETYX™ (cabozantinib) tablets with...

Exelixis And Its Partner Ipsen Announce Phase 3 Trial Results Of CABOMETYX™ (Cabozantinib) Tablets Demonstrating Significant Overall Survival Benefit For Previously Treated Patients With Advanced Renal Cell Carcinoma Presented At ASCO

Exelixis And Its Partner Ipsen Announce Phase 3 Trial Results Of CABOMETYX™ (Cabozantinib) Tablets Demonstrating Significant Overall Survival Benefit For Previously Treated Patients With Advanced Renal Cell Carcinoma Presented At ASCO

Exelixis, Inc. (NASDAQ:EXEL) and Ipsen (Euronext:IPN; ADR:IPSEY) today announced overall survival (OS) results from the phase 3 METEOR trial of CABOMETYX™ (cabozantinib) tablets in patients with advanced renal cell...

Exelixis Announces Genentech Presentation Of Preliminary Phase 1B Trial Results For The Combination Of Cobimetinib And Atezolizumab At ASCO 2016 Annual Meeting

Exelixis Announces Genentech Presentation Of Preliminary Phase 1B Trial Results For The Combination Of Cobimetinib And Atezolizumab At ASCO 2016 Annual Meeting

Exelixis, Inc. (NASDAQ:EXEL) today announced that its collaborator Genentech, a member of the Roche Group, will present preliminary results from a phase 1b clinical trial evaluating the safety and clinical activity of...

Strong On High Volume: Exelixis (EXEL)

Strong On High Volume: Exelixis (EXEL)

Trade-Ideas LLC identified Exelixis (EXEL) as a strong on high relative volume candidate

Exelixis Announces Results From Randomized Phase 2 Trial CABOSUN Demonstrate Cabozantinib Significantly Improved Progression-Free Survival Versus Sunitinib In Previously Untreated Advanced Renal Cell Carcinoma

Exelixis Announces Results From Randomized Phase 2 Trial CABOSUN Demonstrate Cabozantinib Significantly Improved Progression-Free Survival Versus Sunitinib In Previously Untreated Advanced Renal Cell Carcinoma

Exelixis, Inc. (NASDAQ:EXEL) today announced positive top-line results from the CABOSUN randomized phase 2 trial of cabozantinib in patients with previously untreated advanced renal cell carcinoma (RCC).

Exelixis (EXEL) Showing Signs Of Perilous Reversal Today

Exelixis (EXEL) Showing Signs Of Perilous Reversal Today

Trade-Ideas LLC identified Exelixis (EXEL) as a "perilous reversal" (up big yesterday but down big today) candidate

Exelixis To Present At The Bank Of America Merrill Lynch 2016 Health Care Conference On May 10

Exelixis To Present At The Bank Of America Merrill Lynch 2016 Health Care Conference On May 10

Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M.

Exelixis Announces First Quarter 2016 Financial Results And Provides Corporate Update

Exelixis Announces First Quarter 2016 Financial Results And Provides Corporate Update

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2016 and provided an update on progress toward delivering upon its key 2016 corporate objectives and clinical development milestones.

Exelixis To Release First Quarter 2016 Financial Results On Wednesday, May 4, 2016

Exelixis To Release First Quarter 2016 Financial Results On Wednesday, May 4, 2016

Exelixis, Inc. (NASDAQ: EXEL) announced today that its first quarter 2016 financial results will be released on Wednesday, May 4, 2016 after the markets close.

CABOMETYX™ 60 Mg Tablets

CABOMETYX™ 60 Mg Tablets

Exelixis, Inc. (NASDAQ:EXEL) today announced that the U.

Exelixis-Discovered Compounds To Be Featured In 18 Presentations At 2016 ASCO Annual Meeting

Exelixis-Discovered Compounds To Be Featured In 18 Presentations At 2016 ASCO Annual Meeting

Exelixis, Inc. (NASDAQ: EXEL) today announced that new data for cabozantinib, cobimetinib and XL888 will be presented at the upcoming 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June...

Exelixis (EXEL) Stock Climbs, Stifel Upgrades

Exelixis (EXEL) Stock Climbs, Stifel Upgrades

Exelixis (EXEL) stock is rising Monday as Stifel upgraded the stock to ‘buy’ from ‘hold.’

Exelixis To Present At Two Investor Conferences In March

Exelixis To Present At Two Investor Conferences In March

Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M.

Exelixis (EXEL) Stock Climbs on Q4 Results

Exelixis (EXEL) Stock Climbs on Q4 Results

Exelixis (EXEL) stock is jumping on Tuesday after the company reported its 2015 fourth quarter results after yesterday’s market close.